Ratings by BMO Capital (Evan David Seigerman)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/23/2026 | Pfizer | PFE | Maintain | Outperform (N/A) |
|
Details | ||
| 6/22/2026 | Incyte | INCY | Upgrade | Market Perform (Underperform) |
98.99 (108.54) |
9.65% | Details | |
| 6/15/2026 | Incyte | INCY | Maintain | Underperform (N/A) |
|
Details | ||
| 5/18/2026 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/12/2026 | Bristol-Myers Squibb Co. | BMY | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/11/2026 | Protagonist Therapeutics | PTGX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/6/2026 | Neurocrine Bio. | NBIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/4/2026 | Bristol-Myers Squibb Co. | BMY | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/1/2026 | Bristol-Myers Squibb Co. | BMY | Maintain | Market Perform (N/A) |
|
Details | ||
| 4/13/2026 | Pfizer | PFE | Maintain | Outperform (N/A) |
|
Details | ||
| 4/8/2026 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 3/30/2026 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/27/2026 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/26/2026 | Terns Pharmaceuticals | TERN | Downgrade | Market Perform (Outperform) |
52.86 (52.95) |
0.17% | Details | |
| 3/19/2026 | Scholar Rock | SRRK | Maintain | Outperform (N/A) |
|
Details | ||
| 3/11/2026 | BioNTech | BNTX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/9/2026 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/9/2026 | Pfizer | PFE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/9/2026 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 3/3/2026 | Scholar Rock | SRRK | Maintain | Outperform (N/A) |
|
Details | ||
| 3/2/2026 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/26/2026 | Schrodinger | SDGR | Maintain | Outperform (N/A) |
|
Details | ||
| 2/17/2026 | Neurocrine Bio. | NBIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 2/17/2026 | Disc Medicine | IRON | Maintain | Outperform (N/A) |
|
Details | ||
| 2/12/2026 | Neurocrine Bio. | NBIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 2/11/2026 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 2/9/2026 | Biogen | BIIB | Maintain | Market Perform (N/A) |
|
Details | ||
| 2/4/2026 | Merck | MRK | Maintain | Outperform (N/A) |
|
Details | ||
| 2/2/2026 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 1/29/2026 | Disc Medicine | IRON | Maintain | Outperform (N/A) |
|
Details | ||
| 1/26/2026 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 1/15/2026 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 1/13/2026 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 1/12/2026 | BioNTech | BNTX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/19/2025 | Disc Medicine | IRON | Maintain | Outperform (N/A) |
|
Details | ||
| 12/18/2025 | Merck | MRK | Upgrade | Outperform (Market Perform) |
98.27 (120.83) |
22.96% | Details | |
| 12/17/2025 | Pfizer | PFE | Maintain | Outperform (N/A) |
|
Details | ||
| 12/17/2025 | Neurocrine Bio. | NBIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 12/10/2025 | Pfizer | PFE | Maintain | Outperform (N/A) |
|
Details | ||
| 12/9/2025 | Terns Pharmaceuticals | TERN | Maintain | Outperform (N/A) |
|
Details | ||
| 12/4/2025 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 12/3/2025 | Amgen | AMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/25/2025 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 11/20/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/17/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/17/2025 | Scholar Rock | SRRK | Maintain | Outperform (N/A) |
|
Details | ||
| 11/4/2025 | Terns Pharmaceuticals | TERN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/3/2025 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/3/2025 | Neurocrine Bio. | NBIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 10/31/2025 | Merus N.V. | MRUS | Maintain | Market Perform (N/A) |
|
Details | ||
| 10/29/2025 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 10/29/2025 | Neurocrine Bio. | NBIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 10/20/2025 | Incyte | INCY | Maintain | Underperform (N/A) |
|
Details | ||
| 10/20/2025 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 10/20/2025 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 10/20/2025 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 10/13/2025 | Pfizer | PFE | Maintain | Outperform (N/A) |
|
Details | ||
| 10/13/2025 | Protagonist Therapeutics | PTGX | Maintain | Outperform (Underperform) |
|
Details | ||
| 10/8/2025 | Protagonist Therapeutics | PTGX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/1/2025 | Pfizer | PFE | Maintain | Outperform (N/A) |
|
Details | ||
| 9/30/2025 | Pfizer | PFE | Maintain | Outperform (N/A) |
|
Details | ||
| 9/30/2025 | Merus N.V. | MRUS | Downgrade | Market Perform (Outperform) |
68.89 (90.00) |
30.64% | Details | |
| 9/25/2025 | Acadia Pharmaceuticals | ACAD | Maintain | Outperform (N/A) |
|
Details | ||
| 9/24/2025 | Acadia Pharmaceuticals | ACAD | Maintain | Outperform (N/A) |
|
Details | ||
| 9/23/2025 | Pfizer | PFE | Maintain | Outperform (N/A) |
|
Details | ||
| 9/23/2025 | Pfizer | PFE | Maintain | Outperform (N/A) |
|
Details | ||
| 9/22/2025 | Neurocrine Bio. | NBIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 9/17/2025 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 9/11/2025 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 9/5/2025 | BioNTech | BNTX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/27/2025 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 8/21/2025 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 8/6/2025 | Amgen | AMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/5/2025 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/4/2025 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/1/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Market Perform (N/A) |
|
Details | ||
| 7/31/2025 | Neurocrine Bio. | NBIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 7/29/2025 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 7/22/2025 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 7/9/2025 | Amgen | AMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 6/26/2025 | Acadia Pharmaceuticals | ACAD | Maintain | Outperform (N/A) |
|
Details | ||
| 6/24/2025 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 6/24/2025 | Amgen | AMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 6/23/2025 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 6/18/2025 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 6/17/2025 | Disc Medicine | IRON | Maintain | Outperform (N/A) |
|
Details | ||
| 6/3/2025 | Merck | MRK | Maintain | Market Perform (N/A) |
|
Details | ||
| 6/2/2025 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 6/2/2025 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/30/2025 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/30/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/30/2025 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/28/2025 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 5/23/2025 | Merus N.V. | MRUS | Maintain | Outperform (N/A) |
|
Details | ||
| 5/19/2025 | Acadia Pharmaceuticals | ACAD | Maintain | Outperform (N/A) |
|
Details | ||
| 5/16/2025 | Acadia Pharmaceuticals | ACAD | Maintain | Outperform (N/A) |
|
Details | ||
| 5/12/2025 | Disc Medicine | IRON | Maintain | Outperform (N/A) |
|
Details | ||
| 5/6/2025 | Neurocrine Bio. | NBIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 4/28/2025 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 4/23/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Market Perform (N/A) |
|
Details | ||
| 4/21/2025 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 4/17/2025 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 4/17/2025 | Schrodinger | SDGR | Maintain | Outperform (N/A) |
|
Details | ||
| 4/17/2025 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/17/2025 | Pfizer | PFE | Maintain | Outperform (N/A) |
|
Details | ||
| 4/17/2025 | Neurocrine Bio. | NBIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 4/17/2025 | Merck | MRK | Maintain | Market Perform (N/A) |
|
Details | ||
| 4/17/2025 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 4/17/2025 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 4/17/2025 | Biogen | BIIB | Maintain | Market Perform (N/A) |
|
Details | ||
| 4/17/2025 | Acadia Pharmaceuticals | ACAD | Maintain | Outperform (N/A) |
|
Details | ||
| 4/15/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Market Perform (N/A) |
|
Details | ||
| 4/14/2025 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 4/7/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Market Perform (N/A) |
|
Details | ||
| 4/4/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Market Perform (N/A) |
|
Details | ||
| 3/31/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Market Perform (N/A) |
|
Details | ||
| 3/19/2025 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 3/11/2025 | Protagonist Therapeutics | PTGX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/11/2025 | BioNTech | BNTX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/4/2025 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 2/26/2025 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 2/13/2025 | Biogen | BIIB | Maintain | Market Perform (N/A) |
|
Details | ||
| 2/12/2025 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 2/11/2025 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/7/2025 | Neurocrine Bio. | NBIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 2/5/2025 | Merck | MRK | Maintain | Market Perform (N/A) |
|
Details | ||
| 2/3/2025 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 1/31/2025 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 1/29/2025 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 1/29/2025 | Neurocrine Bio. | NBIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 1/29/2025 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 1/29/2025 | Biogen | BIIB | Maintain | Market Perform (N/A) |
|
Details | ||
| 1/29/2025 | Amgen | AMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 1/16/2025 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 1/15/2025 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 12/23/2024 | Novo Nordisk | NVO | Maintain | Outperform (N/A) |
|
Details | ||
| 12/20/2024 | Novo Nordisk | NVO | Maintain | Outperform (N/A) |
|
Details | ||
| 12/20/2024 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/20/2024 | Merck | MRK | Downgrade | Market Perform (Outperform) |
98.34 (98.27) |
-0.07% | Details | |
| 12/20/2024 | Biogen | BIIB | Downgrade | Market Perform (Outperform) |
146.79 (200.92) |
36.88% | Details | |
| 12/18/2024 | Merck | MRK | Maintain | Outperform (Outperform) |
|
Details | ||
| 12/16/2024 | Neurocrine Bio. | NBIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 12/2/2024 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 11/25/2024 | Merck | MRK | Maintain | Outperform (N/A) |
|
Details | ||
| 11/22/2024 | Novo Nordisk | NVO | Maintain | Outperform (N/A) |
|
Details | ||
| 11/18/2024 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 11/12/2024 | Amgen | AMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/12/2024 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 11/12/2024 | Bristol-Myers Squibb Co. | BMY | Maintain | Outperform (N/A) |
|
Details | ||
| 11/5/2024 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 11/5/2024 | Disc Medicine | IRON | Maintain | Outperform (N/A) |
|
Details | ||
| 11/1/2024 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/1/2024 | Merck | MRK | Maintain | Outperform (N/A) |
|
Details | ||
| 11/1/2024 | Bristol-Myers Squibb Co. | BMY | Maintain | Market Perform (N/A) |
|
Details | ||
| 10/31/2024 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 10/31/2024 | Neurocrine Bio. | NBIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 10/31/2024 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 10/28/2024 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 10/21/2024 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/21/2024 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 10/7/2024 | Pfizer | PFE | Maintain | Outperform (N/A) |
|
Details | ||
| 10/3/2024 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 10/2/2024 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 9/30/2024 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 9/27/2024 | Bristol-Myers Squibb Co. | BMY | Maintain | Market Perform (N/A) |
|
Details | ||
| 9/26/2024 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 9/26/2024 | Pfizer | PFE | Maintain | Outperform (N/A) |
|
Details | ||
| 9/25/2024 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 9/25/2024 | Amgen | AMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 9/23/2024 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 9/23/2024 | Novo Nordisk | NVO | Maintain | Outperform (N/A) |
|
Details | ||
| 9/23/2024 | Bristol-Myers Squibb Co. | BMY | Maintain | Market Perform (N/A) |
|
Details | ||
| 9/20/2024 | Novo Nordisk | NVO | Maintain | Outperform (N/A) |
|
Details | ||
| 9/17/2024 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 9/13/2024 | Pfizer | PFE | Maintain | Outperform (N/A) |
|
Details | ||
| 9/13/2024 | Neurocrine Bio. | NBIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 9/13/2024 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 9/12/2024 | Gilead Sciences | GILD | Maintain | Outperform (Outperform) |
|
Details | ||
| 9/12/2024 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 9/11/2024 | Novo Nordisk | NVO | Maintain | Outperform (N/A) |
|
Details | ||
| 9/9/2024 | Merck | MRK | Maintain | Outperform (N/A) |
|
Details | ||
| 9/5/2024 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 8/28/2024 | Neurocrine Bio. | NBIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 8/27/2024 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 8/22/2024 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 8/15/2024 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 8/9/2024 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 8/9/2024 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 8/8/2024 | Novo Nordisk | NVO | Maintain | Outperform (N/A) |
|
Details | ||
| 7/19/2024 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 7/12/2024 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 7/12/2024 | Pfizer | PFE | Maintain | Outperform (N/A) |
|
Details | ||
| 7/8/2024 | Eli Lilly | LLY | Maintain | Outperform (Outperform) |
|
Details | ||
| 7/2/2024 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 6/25/2024 | Novo Nordisk | NVO | Maintain | Outperform (N/A) |
|
Details | ||
| 6/20/2024 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 6/17/2024 | Disc Medicine | IRON | Maintain | Outperform (N/A) |
|
Details | ||
| 6/13/2024 | Disc Medicine | IRON | Maintain | Outperform (N/A) |
|
Details | ||
| 6/4/2024 | Merck | MRK | Maintain | Outperform (N/A) |
|
Details | ||
| 6/3/2024 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 6/3/2024 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 6/3/2024 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 5/31/2024 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/30/2024 | Merck | MRK | Maintain | Outperform (N/A) |
|
Details | ||
| 5/23/2024 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 5/23/2024 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 5/20/2024 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 5/20/2024 | Amgen | AMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/17/2024 | Amgen | AMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/3/2024 | Amgen | AMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/2/2024 | Pfizer | PFE | Maintain | Outperform (N/A) |
|
Details | ||
| 5/2/2024 | Neurocrine Bio. | NBIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 4/30/2024 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 4/30/2024 | Incyte | INCY | Maintain | Market Perform (N/A) |
|
Details | ||
| 4/29/2024 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 4/26/2024 | Bristol-Myers Squibb Co. | BMY | Maintain | Market Perform (N/A) |
|
Details | ||
| 4/24/2024 | Incyte | INCY | Maintain | Market Perform (N/A) |
|
Details | ||
| 4/24/2024 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 4/18/2024 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 4/12/2024 | Amgen | AMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/12/2024 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 4/12/2024 | Novo Nordisk | NVO | New Coverage | Outperform (N/A) |
124.93 (47.27) |
-62.16% | Details | |
| 4/2/2024 | Disc Medicine | IRON | Maintain | Outperform (N/A) |
|
Details | ||
| 3/15/2024 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 2/29/2024 | Disc Medicine | IRON | Maintain | Outperform (N/A) |
|
Details | ||
| 2/14/2024 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 2/14/2024 | Incyte | INCY | Maintain | Market Perform (N/A) |
|
Details | ||
| 2/7/2024 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 2/5/2024 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 12/19/2023 | Amgen | AMGN | Upgrade | Outperform (Market Perform) |
275.45 (352.64) |
28.02% | Details | |
| 12/11/2023 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 11/20/2023 | Bristol-Myers Squibb Co. | BMY | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/10/2023 | Neurocrine Bio. | NBIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/9/2023 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 11/7/2023 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/27/2023 | Bristol-Myers Squibb Co. | BMY | Downgrade | Market Perform (Outperform) |
56.61 (55.18) |
-2.53% | Details | |
| 10/27/2023 | Merck | MRK | Upgrade | Outperform (Market Perform) |
103.63 (98.34) |
-5.1% | Details | |
| 10/16/2023 | Pfizer | PFE | Maintain | Outperform (N/A) |
|
Details | ||
| 10/6/2023 | Mirati Therapeutics | MRTX | Maintain | Market Perform (N/A) |
|
Details | ||
| 9/12/2023 | Neurocrine Bio. | NBIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 8/21/2023 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/8/2023 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 8/4/2023 | Amgen | AMGN | Maintain | Market Perform (N/A) |
|
Details | ||
| 8/2/2023 | Neurocrine Bio. | NBIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 8/2/2023 | Incyte | INCY | Maintain | Market Perform (N/A) |
|
Details | ||
| 8/2/2023 | Pfizer | PFE | Maintain | Outperform (N/A) |
|
Details | ||
| 8/2/2023 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 7/28/2023 | Bristol-Myers Squibb Co. | BMY | Maintain | Outperform (N/A) |
|
Details | ||
| 7/26/2023 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 7/6/2023 | Neurocrine Bio. | NBIX | Upgrade | Market Perform (Underperform) |
94.48 (166.37) |
76.09% | Details | |
| 6/12/2023 | Disc Medicine | IRON | Maintain | Outperform (N/A) |
|
Details | ||
| 5/25/2023 | Mirati Therapeutics | MRTX | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/16/2023 | Gilead Sciences | GILD | Upgrade | Outperform (Market Perform) |
78.17 (125.60) |
60.68% | Details | |
| 5/15/2023 | Candel Therapeutics Inc. | CADL | Maintain | Outperform (N/A) |
|
Details | ||
| 5/4/2023 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 5/3/2023 | Incyte | INCY | Maintain | Market Perform (N/A) |
|
Details | ||
| 3/24/2023 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/23/2023 | Disc Medicine | IRON | New Coverage | Outperform (N/A) |
22.24 (71.17) |
220.01% | Details | |
| 3/14/2023 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/1/2023 | Mirati Therapeutics | MRTX | Maintain | Market Perform (N/A) |
|
Details | ||
| 2/3/2023 | Merck | MRK | Maintain | Market Perform (N/A) |
|
Details | ||
| 2/1/2023 | Pfizer | PFE | Maintain | Outperform (N/A) |
|
Details | ||
| 2/1/2023 | Amgen | AMGN | Maintain | Market Perform (N/A) |
|
Details | ||
| 12/20/2022 | Gilead Sciences | GILD | Maintain | Market Perform (N/A) |
|
Details | ||
| 12/20/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Outperform (N/A) |
|
Details | ||
| 12/20/2022 | Amgen | AMGN | Maintain | Market Perform (N/A) |
|
Details | ||
| 12/14/2022 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 12/8/2022 | Mirati Therapeutics | MRTX | Downgrade | Market Perform (Outperform) |
71.52 (58.70) |
-17.93% | Details | |
| 11/4/2022 | Amgen | AMGN | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/2/2022 | Neurocrine Bio. | NBIX | Maintain | Underperform (N/A) |
|
Details | ||
| 10/28/2022 | Merck | MRK | Maintain | Market Perform (N/A) |
|
Details | ||
| 10/21/2022 | Pfizer | PFE | Maintain | Outperform (N/A) |
|
Details | ||
| 10/21/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Outperform (N/A) |
|
Details | ||
| 10/21/2022 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 9/28/2022 | Biogen | BIIB | Upgrade | Outperform (Market Perform) |
195.75 (146.79) |
-25.01% | Details | |
| 9/22/2022 | Pfizer | PFE | Maintain | Outperform (N/A) |
|
Details | ||
| 9/12/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Outperform (N/A) |
|
Details | ||
| 9/8/2022 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 9/6/2022 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 8/3/2022 | Gilead Sciences | GILD | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 8/2/2022 | Incyte | INCY | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 7/20/2022 | Biogen | BIIB | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 7/19/2022 | Incyte | INCY | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 7/11/2022 | Vertex | VRTX | Maintain | Outperform (Outperform) |
|
Details | ||
| 7/5/2022 | Vertex | VRTX | Maintain | Outperform (Outperform) |
|
Details | ||
| 6/24/2022 | Regeneron Pharma | REGN | Maintain | Outperform (Outperform) |
|
Details | ||
| 6/7/2022 | Mirati Therapeutics | MRTX | Maintain | Outperform (Outperform) |
|
Details | ||
| 6/6/2022 | Gilead Sciences | GILD | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 5/6/2022 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 5/4/2022 | Neurocrine Bio. | NBIX | Maintain | Underperform (Underperform) |
|
Details | ||
| 5/4/2022 | Regeneron Pharma | REGN | Maintain | Outperform (Outperform) |
|
Details | ||
| 5/3/2022 | Biogen | BIIB | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 5/2/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Outperform (N/A) |
|
Details | ||
| 4/29/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Outperform (Outperform) |
|
Details | ||
| 4/28/2022 | Gilead Sciences | GILD | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 4/28/2022 | Eli Lilly | LLY | Maintain | Outperform (Outperform) |
|
Details | ||
| 4/27/2022 | Amgen | AMGN | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 4/19/2022 | Regeneron Pharma | REGN | Maintain | Outperform (Outperform) |
|
Details | ||
| 4/7/2022 | Pfizer | PFE | Maintain | Outperform (Outperform) |
|
Details | ||
| 4/5/2022 | Merck | MRK | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/31/2022 | Candel Therapeutics Inc. | CADL | Maintain | Outperform (N/A) |
|
Details | ||
| 3/30/2022 | Amgen | AMGN | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 3/30/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Outperform (N/A) |
|
Details | ||
| 3/29/2022 | Regeneron Pharma | REGN | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/23/2022 | Pfizer | PFE | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/22/2022 | Vertex | VRTX | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/15/2022 | Biogen | BIIB | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/14/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/7/2022 | Biogen | BIIB | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 3/7/2022 | Gilead Sciences | GILD | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 3/4/2022 | Gilead Sciences | GILD | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 3/1/2022 | Pfizer | PFE | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/1/2022 | Mirati Therapeutics | MRTX | Maintain | Outperform (Outperform) |
|
Details | ||
| 2/28/2022 | Gilead Sciences | GILD | Downgrade | Market Perform (Outperform) |
60.61 (78.17) |
28.97% | Details | |
| 2/16/2022 | Biogen | BIIB | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 2/16/2022 | Gilead Sciences | GILD | Maintain | Outperform (Outperform) |
|
Details | ||
| 2/15/2022 | Amgen | AMGN | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 2/14/2022 | Neurocrine Bio. | NBIX | Maintain | Underperform (N/A) |
|
Details | ||
| 2/11/2022 | Neurocrine Bio. | NBIX | Maintain | Underperform (Underperform) |
|
Details | ||
| 2/11/2022 | Regeneron Pharma | REGN | Maintain | Outperform (Outperform) |
|
Details | ||
| 2/11/2022 | Neurocrine Bio. | NBIX | Maintain | Outperform (Outperform) |
|
Details | ||
| 2/8/2022 | Amgen | AMGN | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 2/8/2022 | Incyte | INCY | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 2/8/2022 | Pfizer | PFE | Maintain | Outperform (Outperform) |
|
Details | ||
| 2/7/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Outperform (N/A) |
|
Details | ||
| 2/4/2022 | Regeneron Pharma | REGN | Maintain | Outperform (Outperform) |
|
Details | ||
| 2/4/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Outperform (Outperform) |
|
Details | ||
| 2/4/2022 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 2/4/2022 | Biogen | BIIB | Downgrade | Market Perform (Outperform) |
220.17 (200.92) |
-8.74% | Details | |
| 2/3/2022 | Biogen | BIIB | Maintain | Outperform (Outperform) |
|
Details | ||
| 2/3/2022 | Merck | MRK | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 2/3/2022 | Eli Lilly | LLY | Maintain | Outperform (Outperform) |
|
Details | ||
| 2/2/2022 | Gilead Sciences | GILD | Maintain | Outperform (Outperform) |
|
Details | ||
| 1/26/2022 | Vertex | VRTX | Maintain | Outperform (Outperform) |
|
Details | ||
| 1/20/2022 | Vertex | VRTX | Upgrade | Outperform (Market Perform) |
231.07 (477.05) |
106.45% | Details | |
| 1/14/2022 | Pfizer | PFE | Maintain | Outperform (Outperform) |
|
Details | ||
| 1/13/2022 | Gilead Sciences | GILD | Maintain | Outperform (Outperform) |
|
Details | ||
| 1/13/2022 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 12/16/2021 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 11/19/2021 | Neurocrine Bio. | NBIX | New Coverage | Underperform (N/A) |
89.60 (166.37) |
85.68% | Details | |
| 11/19/2021 | Vertex | VRTX | New Coverage | Market Perform (N/A) |
188.25 (477.05) |
153.41% | Details | |
| 11/19/2021 | Merck | MRK | New Coverage | Market Perform (N/A) |
82.60 (120.83) |
46.28% | Details | |
| 11/19/2021 | Incyte | INCY | New Coverage | Market Perform (N/A) |
65.02 (60.62) |
-6.77% | Details | |
| 11/19/2021 | Amgen | AMGN | New Coverage | Market Perform (N/A) |
205.82 (352.64) |
71.33% | Details | |
| 11/19/2021 | Regeneron Pharma | REGN | New Coverage | Outperform (N/A) |
641.83 (625.41) |
-2.56% | Details | |
| 11/19/2021 | Pfizer | PFE | New Coverage | Outperform (N/A) |
50.87 (24.08) |
-52.66% | Details | |
| 11/19/2021 | Mirati Therapeutics | MRTX | New Coverage | Outperform (N/A) |
138.50 (58.70) |
-57.62% | Details | |
| 11/19/2021 | Eli Lilly | LLY | New Coverage | Outperform (N/A) |
261.18 (1111.52) |
325.58% | Details | |
| 11/19/2021 | Candel Therapeutics Inc. | CADL | New Coverage | Outperform (N/A) |
10.60 (9.35) |
-11.79% | Details | |
| 11/19/2021 | Gilead Sciences | GILD | New Coverage | Outperform (N/A) |
67.46 (125.60) |
86.18% | Details | |
| 11/19/2021 | Bristol-Myers Squibb Co. | BMY | New Coverage | Outperform (N/A) |
59.44 (55.18) |
-7.17% | Details | |
| 11/19/2021 | Biogen | BIIB | New Coverage | Outperform (N/A) |
258.38 (200.92) |
-22.24% | Details |
